EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells

Supreet Khanal, Nirjal Bhattarai

Methods and Protocols · 05.09.2025 · 8 (5) · 102

DOI: 10.3390/mps8050102 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Methods and Protocols, online erschienen am 05.09.2025. Verfasst von Supreet Khanal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Vaccine and Biotechnology Branch, Division of Cell Therapy II, Office of Cellular Therapy and Human Tissues, Office of Therapeutic Products, Ce…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor-expressing NK (CAR-NK) cells represent an advancing frontier in cancer immunotherapy, building upon decades of natural killer cell research and recent breakthroughs in CAR technology. While early CAR-NK manufacturing protocols have demonstrated feasibility, existing manufacturing methods, whether utilizing cord blood or peripheral blood sources, often require extended culture periods and intensive labor, creating bottlenecks for widespread therapeutic application. To address these manufacturing hurdles, we have developed an optimized protocol for ex vivo CAR-NK cell production from human peripheral blood that incorporates lessons learned from previous methodologies while introducing novel efficiency improvements. This protocol offers a practical solution for scalable CAR-NK cell manufacturing that can be readily adapted across different production facilities, potentially accelerating the clinical development of CAR-NK therapies.

Schlagwörter

Stichwörter der Autor:innen

CAR-NKG-Rexcell manufacturingchimeric antigen receptorexpansion

Autor:innen und Institutionen

  • Tumor Vaccine and Biotechnology Branch, Division of Cell Therapy II, Office of Cellular Therapy and Human Tissues, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. FDA, Silver Spring, M…

Förderung

  • Intramural Research Program of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration

Zitieren

APA

Khanal, S., & Bhattarai, N. (2025). A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells. Methods and Protocols, 8(5), 102. https://doi.org/10.3390/mps8050102

Vancouver

Khanal S, Bhattarai N. A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells. Methods and Protocols. 2025;8(5):102. doi:10.3390/mps8050102

BibTeX
@article{Khanal2025,
  author = {Khanal, Supreet and Bhattarai, Nirjal},
  title = {A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells},
  journal = {Methods and Protocols},
  year = {2025},
  volume = {8},
  number = {5},
  pages = {102},
  doi = {10.3390/mps8050102}
}
Kostenlos starten →